Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

NCT02057575 ↗

Phase 2 Completed 298 enrolled Aerie Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.

Timeline

Start: 2014-01
Primary completion: 2014-06
Completion: 2014-06

Publications

Lewis RA, Levy B, Ramirez N, Kopczynski CC, Usner DW, Novack GD; PG324-CS201 Study Group. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2016 Mar;100(3):339-44. doi: 10.1136/bjophthalmol-2015-306778. Epub 2015 Jul 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Latanoprost	Small molecule	0.005 %	—
Subject	Netarsudil	Small molecule	0.01 %	—
Subject	Netarsudil	Small molecule	0.02 %	—

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Summary

Timeline

Publications

Drugs

Indications